… for rebound in malaria cases (also referred to as “age shift”) as immunity wanes may lessen
the public health usefulness of malaria vaccines. We present data from 7 years of follow-up …

… malaria when used along with other measures [3]. A minimally 50% efficacious malaria
vaccine that lasts at least a year is critical to the 2015 landmark goals of the Malaria Vaccine …

… We did a randomised, open-label, phase 2 trial of safety and efficacy of the RTS,S/AS01 E
candidate malaria vaccine given with EPI vaccines between April 30, 2007, and Oct 7, 2009, …

… Here we present data on efficacy after 4 years of follow-up in Kilifi, Kenya. … time since
vaccination and vaccine efficacy and between level of exposure to malaria and vaccine efficacy. …

… malaria vaccine and parasitic vaccine, RTS,S/AS01 (RTS,S, also known as Mosquirix™) for
widespread use. The vaccine significantly reduces total malaria … Given that a malaria vaccine …

… Malaria Vaccine Initiative (MVI) supports the development and testing of a number of malaria
vaccines that … Both JC and WRB are listed as the “inventors” of patented malaria vaccines. …

… effective malaria vaccines are needed. In this review, we discuss malaria vaccine candidates
… : Sanaria’s irradiated sporozoite vaccine (PfSPZ Vaccine), the chemoattenuated sporozoite …

… , and efficacy trial of this novel pre-erythrocytic malaria vaccine candidate in children aged
5–17 months in Nanoro, Burkina Faso. To ensure antibody responses were highest during the …

… the candidate malaria vaccine or a licensed rabies vaccine in … Vaccinations took place
over a 6-month period from March … for malaria began 2.5 months after the first vaccination and …

… Malaria is a leading cause of morbidity and mortality worldwide. We … the efficacy of the
R21/Matrix-M malaria vaccine, which reached the WHO-specified goal of 75% or greater efficacy …